tiprankstipranks
Blurbs

Analysts Are Bullish on Top Technology Stocks: Erasca (ERAS), Synaptics (SYNA)

There’s a lot to be optimistic about in the Technology sector as 3 analysts just weighed in on Erasca (ERASResearch Report), Synaptics (SYNAResearch Report) and 908 Devices (MASSResearch Report) with bullish sentiments.

Erasca (ERAS)

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Erasca today and set a price target of $10.00. The company’s shares closed last Thursday at $2.01, close to its 52-week low of $1.82.

According to TipRanks.com, Maldonado is a 4-star analyst with an average return of 9.0% and a 53.6% success rate. Maldonado covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Werewolf Therapeutics, and Scholar Rock Holding.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Erasca with a $9.75 average price target, which is a 329.5% upside from current levels. In a report released yesterday, Goldman Sachs also maintained a Buy rating on the stock with a $6.00 price target.

See the top stocks recommended by analysts >>

Synaptics (SYNA)

In a report released today, Krish Sankar from TD Cowen maintained a Buy rating on Synaptics, with a price target of $115.00. The company’s shares closed last Thursday at $88.50.

According to TipRanks.com, Sankar is a 5-star analyst with an average return of 15.2% and a 61.7% success rate. Sankar covers the Technology sector, focusing on stocks such as Taiwan Semiconductor Manufacturing, Ultra Clean Holdings, and GlobalFoundries Inc.

Synaptics has an analyst consensus of Strong Buy, with a price target consensus of $109.17, implying a 22.0% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $115.00 price target.

908 Devices (MASS)

In a report issued on November 7, Puneet Souda from Leerink Partners reiterated a Buy rating on 908 Devices, with a price target of $15.00. The company’s shares closed last Thursday at $4.96.

According to TipRanks.com, Souda is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.8% and a 33.8% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Guardant Health.

908 Devices has an analyst consensus of Moderate Buy, with a price target consensus of $15.00, which is a 161.8% upside from current levels. In a report issued on November 7, TD Cowen also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ERAS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles